{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:37:18Z","timestamp":1762875438098,"version":"3.44.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.ando.2012.03.024","type":"journal-article","created":{"date-parts":[[2012,4,13]],"date-time":"2012-04-13T08:47:02Z","timestamp":1334306822000},"page":"90-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["2012 update in the treatment of prolactinomas"],"prefix":"10.1016","volume":"73","author":[{"given":"Dominique","family":"Maiter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Primeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2012.03.024_bib0005","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege Belgium","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0015","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1210\/jc.2010-0537","article-title":"Incidence of pituitary adenomas in Northern Finland in 1992-2007","volume":"95","author":"Raappana","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0020","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMcp025334","article-title":"Clinical practice. Prolactinoma","volume":"349","author":"Schlechte","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2012.03.024_bib0025","series-title":"Pituitary","article-title":"Prolactinoma","author":"Molitch","year":"2002"},{"key":"10.1016\/j.ando.2012.03.024_bib0030","first-page":"2102","article-title":"Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study","volume":"82","author":"Delgrange","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0040","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2012.03.024_bib0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia. An endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0050","series-title":"Williams textbook of Endocrinology","article-title":"Anterior pituitary","author":"Melmed","year":"2009"},{"key":"10.1016\/j.ando.2012.03.024_bib0055","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2265.2006.02627.x","article-title":"Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma","volume":"65","author":"Karavitaki","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/EJE-10-0255","article-title":"Factors predicting relapse of non-functioning pituitary macroadenomas after neurosurgery: a study of 142 patients","volume":"163","author":"Brochier","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0065","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0015-0282(16)55819-1","article-title":"The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia","volume":"59","author":"Corenblum","year":"1993","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ando.2012.03.024_bib0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0010-7824(98)00069-9","article-title":"Two-year treatment with oral contraceptives in hyperprolactinemic patients","volume":"58","author":"Testa","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.ando.2012.03.024_bib0075","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2265.2006.02493.x","article-title":"Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy","volume":"64","author":"Delgrange","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0080","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2265.2007.02759.x","article-title":"Macroprolactinomas and epilepsy","volume":"66","author":"Deepak","year":"2007","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0085","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.2.5916.419","article-title":"Long-term treatment of galactorrhea and hypogonadism with bromocriptine","volume":"2","author":"Thorner","year":"1974","journal-title":"BMJ"},{"key":"10.1016\/j.ando.2012.03.024_bib0090","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/beem.1999.0030","article-title":"Clinical management of prolactinomas","volume":"13","author":"Webster","year":"1999","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0095","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2012.03.024_bib0100","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0105","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1530\/eje.0.1340454","article-title":"Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine","volume":"134","author":"Delgrange","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/eje.1.02075","article-title":"Quinagolide - a valuable treatment option for hyperprolactinaemia","volume":"154","author":"Barlier","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0115","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients","volume":"160","author":"Delgrange","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0120","first-page":"4","article-title":"Macroad\u00e9nome hypophysaire \u00e0 prolactine\u00a0: traitement par la cabergoline","author":"Delgrange","year":"2004","journal-title":"Med Clin Endocrinol Diab"},{"key":"10.1016\/j.ando.2012.03.024_bib0125","first-page":"2247","article-title":"Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0130","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1046\/j.1365-2265.2003.01770.x","article-title":"Giant prolactinomas in men: efficacity of cabergoline treatment","volume":"58","author":"Corsello","year":"2003","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0140","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","volume":"349","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2012.03.024_bib0145","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","article-title":"Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy","volume":"94","author":"Kharlip","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0150","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1210\/jc.2009-0999","article-title":"Dopamine agonist therapy in prolactinomas: when can treatment be discontinued?","volume":"94","author":"Klibanski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0155","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/jc.2007-0836","article-title":"Long-term management of prolactinomas","volume":"92","author":"Schlechte","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2012.03.024_bib0165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2012.03.024_bib0170","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease","volume":"363","author":"Van Camp","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2012.03.024_bib0175","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2012.03.024_bib0180","first-page":"251","article-title":"Differential effects of dopamine agonists at D2s and 5HT2B receptors","volume":"19","author":"Igbokwe","year":"2009","journal-title":"Program Br Endocr Soc"},{"key":"10.1016\/j.ando.2012.03.024_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-08-0213","article-title":"Cabergoline and the risk of valvular lesions in endocrine disease","volume":"159","author":"Lancellotti","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0190","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1742-1241.2008.01779.x","article-title":"Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia","volume":"62","author":"Bogazzi","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ando.2012.03.024_bib0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11102-008-0134-2","article-title":"Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas","volume":"12","author":"Vallette","year":"2009","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2012.03.024_bib0200","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","article-title":"Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma","volume":"93","author":"Kars","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0205","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","article-title":"Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-08-0365","article-title":"Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease","volume":"159","author":"Wakil","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2265.2009.03608.x","article-title":"Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study","volume":"72","author":"Nachtigall","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0220","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2265.2008.03458.x","article-title":"Valvular heart disease and the use of cabergoline for the treatment of prolactinoma","volume":"70","author":"Herring","year":"2009","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0225","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1530\/EJE-09-0989","article-title":"Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline","volume":"162","author":"Lafeber","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0230","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2265.2010.03827.x","article-title":"Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia","volume":"73","author":"Tan","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0235","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-08-0611","article-title":"Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required","volume":"159","author":"Kars","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0240","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1210\/jc.2009-2095","article-title":"Potential cardiac valve effects of dopamine agonists in hyperprolactinemia","volume":"95","author":"Valassi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0245","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2265.2011.04326.x","article-title":"Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study","author":"Delgado","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0250","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","article-title":"Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas","volume":"34","author":"Martinkova","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ando.2012.03.024_bib0255","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","article-title":"Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma","volume":"19","author":"Davie","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.ando.2012.03.024_bib0260","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0265","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1210\/jc.2008-2244","article-title":"The cabergoline-resistant prolactinoma patient: new challenges","volume":"93","author":"Molitch","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0270","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0275","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ecl.2007.10.005","article-title":"Radiotherapy for pituitary adenomas","volume":"37","author":"Brada","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ando.2012.03.024_bib0280","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/eje.1.02268","article-title":"Malignant prolactinoma: Case report and review of the literature","volume":"155","author":"Kars","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0285","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1210\/jc.2004-2231","article-title":"Diagnosis and management of pituitary carcinomas","volume":"90","author":"Kaltsas","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0290","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-09-0389","article-title":"Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy, Case Report","volume":"161","author":"Hagen","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0295","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/cncr.25413","article-title":"Treatment of pituitary neoplasms with temozolomide: a review","volume":"117","author":"Syro","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2012.03.024_bib0300","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1210\/jc.2010-0644","article-title":"Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: A French multicenter experience","volume":"95","author":"Raverot","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0305","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1210\/jcem.87.7.8645","article-title":"Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome","volume":"87","author":"Losa","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0310","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3171\/jns.2002.97.2.0307","article-title":"Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery","volume":"97","author":"Amar","year":"2002","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ando.2012.03.024_bib0315","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11102-005-5086-1","article-title":"Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists","volume":"8","author":"Hamilton","year":"2005","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2012.03.024_bib0320","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-07-0248","article-title":"Operative treatment of prolactinomas: indications and results in current consecutive series of 212 patients","volume":"158","author":"Kreutzer","year":"2008","journal-title":"Eur J of Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0325","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1210\/jc.2009-1191","article-title":"Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a post-operative follow-up","volume":"95","author":"Raverot","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0330","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2265.1992.tb02900.x","article-title":"Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests","volume":"36","author":"Webster","year":"1992","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0335","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0090-3019(95)00430-0","article-title":"Transsphenoidal adenomectomy for microprolactinomas: 10-20 years of follow-up","volume":"45","author":"Massoud","year":"1996","journal-title":"Surg Neurol"},{"key":"10.1016\/j.ando.2012.03.024_bib0340","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00006123-199902000-00006","article-title":"Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results","volume":"44","author":"Tyrrell","year":"1999","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ando.2012.03.024_bib0345","first-page":"370","article-title":"Clinical characteristics and prognostic factors in a cohort of 70 patients operated for prolactinoma","volume":"72","author":"Primeau","year":"2011","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0350","first-page":"1121","article-title":"Management of prolactinomas during pregnancy","volume":"44","author":"Molitch","year":"1999","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ando.2012.03.024_bib0355","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.1982.03320360039028","article-title":"Surveillance of bromocriptine in pregnancy","volume":"247","author":"Turkalj","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.ando.2012.03.024_bib0360","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/BF01727477","article-title":"Bromocriptine in pregnancy: safety aspects","volume":"65","author":"Krupp","year":"1987","journal-title":"Wien Klin Wochensch"},{"key":"10.1016\/j.ando.2012.03.024_bib0365","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1185\/03007998609110437","article-title":"The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review","volume":"10","author":"Weil","year":"1986","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ando.2012.03.024_bib0370","first-page":"885","article-title":"Prolactinoma in pregnancy. Best Practice","volume":"25","author":"Molitch","year":"2011","journal-title":"Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0375","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0890-6238(02)00055-2","article-title":"Pregnancy outcome after cabergoline treatment in early weeks of gestation","volume":"16","author":"Ricci","year":"2002","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.ando.2012.03.024_bib0380","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2265.2007.03000.x","article-title":"Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study","volume":"68","author":"Colao","year":"2008","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0385","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2265.2010.03808.x","article-title":"Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women","volume":"73","author":"Lebbe","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2012.03.024_bib0390","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1210\/jc.2009-2605","article-title":"Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas","volume":"95","author":"Ono","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.03.024_bib0395","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11102-010-0243-6","article-title":"Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature","volume":"13","author":"Stalldecker","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2012.03.024_bib0400","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2265.1996.00824.x","article-title":"Long-term follow-up of patients with hyperprolactinaemia","volume":"45","author":"Jeffcoate","year":"1996","journal-title":"Clin Endocrinol"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426612000480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426612000480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:45:36Z","timestamp":1757717136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426612000480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0003426612000480"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2012.03.024","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2012 update in the treatment of prolactinomas","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2012.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}